Search
06 Sept 2025
Search
06 Sept 2025
Please allow ads as they help fund our trusted local news content.
Kindly add us to your ad blocker whitelist.
If you want further access to Ireland's best local journalism, consider contributing and/or subscribing to our free daily Newsletter .
Support our mission and join our community now.
To continue reading this article, you can subscribe for as little as €0.50 per week which will also give you access to all of our premium content and archived articles!
Alternatively, you can pay €0.50 per article, capped at €1 per day.
Thank you for supporting Ireland's best local journalism!
Drugs to treat cancer and eczema are among those which have been newly approved for routine use on the NHS in Scotland.
The Scottish Medicines Consortium (SMC) has accepted axicabtagene ciloleucel, known by the brand name Yescarta, for treating adults with two types of blood cancer: diffuse large B-cell lymphoma and high-grade B-cell lymphoma; when they have received only one line of therapy.
Lebrikizumab (Ebglyss) was accepted for the treatment of adults and children 12 years and older with moderate to severe atopic dermatitis, a type of eczema.
Quizartinib (Vanflyta) was accepted to treat adult patients with newly diagnosed acute myeloid leukaemia where the cancer cells have a particular mutation.
Linzagolix (Yselty) was recommended for treating adults with moderate to severe symptoms from uterine fibroids, which are benign growths in the womb.
Somapacitan (Sogroya) was accepted for the treatment of children and adolescents with growth hormone deficiency.
Tenecteplase (Metalyse) was accepted to treat adults who have suffered a stroke caused by a blockage in a blood vessel, known as an ischaemic stroke.
Pembrolizumab (Keytruda) was not recommended for treating adults with non-small cell lung cancer at high risk of recurrence following surgery.
SMC chair Dr Scott Muir said: “The committee is pleased to be able to accept these new medicines for use by NHS Scotland.
“The committee heard from patient representatives about the heavy symptom burden of lymphoma and the expected benefits axicabtagene ciloleucel could bring.
“Patient group representatives shared the substantial impact that atopic dermatitis can have on those affected.
“Our decision on lebrikizumab provides another treatment option which may allow some patients to better manage their condition.
“The committee was not able to accept pembrolizumab for the treatment of non-small cell lung cancer in this setting, due to the uncertainties in the evidence presented when compared to current treatments.”
Subscribe or register today to discover more from DonegalLive.ie
Buy the e-paper of the Donegal Democrat, Donegal People's Press, Donegal Post and Inish Times here for instant access to Donegal's premier news titles.
Keep up with the latest news from Donegal with our daily newsletter featuring the most important stories of the day delivered to your inbox every evening at 5pm.
This publication supports the work of the Press Council of Ireland and Office of the Press Ombudsman, and our staff operate within the Code of Practice of the Press Council. You can obtain a copy of the Code, or contact the Council, at www.presscouncil.ie, Lo-call 1800 208 080 or email: info@presscouncil.ie.
